₹ 256000 / 2000 Shares Shares
Minimum Investment
₹120-128 per equity share
07 Nov 2025
11 Nov 2025
1000
₹ 256000
₹120-128
14 Nov 2025
21,50,000 shares(aggregating up to ₹27.52 crore)
₹10 Per Equity Share
2000 Shares
2000 Shares
Established in 2010, Curis Lifesciences Limited is a pharmaceutical company specializing in the development, manufacturing, and distribution of a diverse range of products. The company manufactures pharmaceutical products both internationally and nationally on a loan license or on a contract basis, and for own brand marketing.The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya. Curis Lifesciences specializes in the development, manufacturing, and distribution of a broad array of pharmaceutical products that include: General pharmaceutical tablets and capsules Oral liquids External preparations Sterile ophthalmic ointments The firm has a state-of-the-art manufacturing facility in Sanand, Gujarat, operating under strict quality control measures to ensure the safety and efficacy of its products.The company offers different pharmaceutical formulations and products made on a contract basis.They provide tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. As of June 30, 2024, the company has 93 permanent employees.
2020
Dharmesh Dasharathbhai Patel
Curis Lifesciences Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Individual (min) | ₹120-128 | ₹2,56,000 |
| Individual(max) | ₹120-128 | ₹2,56,000 |
| SHNI(min) | ₹120-128 | ₹3,84,000 |
| SHNI(max) | ₹120-128 | ₹8,96,000 |
| BHNI(min) | ₹120-128 | ₹10,24,000 |
Apply for all eligible candidates, Curis Lifesciences Limited IPO.
KSquare simplifies the process by partnering with lenders and offering a smooth, digital journey from application to disbursal.
SIPs help average out market volatility over time, making them a safer and more consistent choice than lump sum investing.
The loan value is based on the mutual fund's NAV and the lender’s margin requirements. KSquare shows your eligible amount during application.
NFOs are ideal for long-term investors who can wait for the fund to build performance and portfolio over time.
Yes, SIPs in ELSS funds qualify for tax deductions under Section 80C up to ₹1.5 lakh annually.
Yes, KSquare offers fund highlights, investment strategy, and expert opinions to help you evaluate each NFO thoroughly.
KSquare offers expert analysis, transparent insights, and seamless access to promising NFOs aligned with your goals.
In case of default, the lender may sell pledged mutual fund units. KSquare advises timely repayment to avoid any financial impact.